Patents Assigned to La Jolla Cancer Research Foundation
-
Patent number: 6100236Abstract: The invention provides RGD containing peptides which are cyclized and contain hydrophobic moieties adjacent the carboxy terminus of the RGD sequence. Such peptides have an high affinity for the receptor IIb/IIIa and low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.Type: GrantFiled: June 5, 1995Date of Patent: August 8, 2000Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig
-
Patent number: 6100243Abstract: The present invention is directed to methods of sensitizing a human tumor cell with adenovirus E1A. The methods involve treating a human tumor cell by, first, introducing into the tumor cell nucleic acid encoding a polypeptide having adenovirus E1A activity, expressing the E1A active polypeptide in the cell, and then either contacting the E1A expressing tumor cell with a chemotherapeutic agent or irradiating the E1A-expressing tumor cell. The invention also provides methods of enhancing a subject's response to chemotherapy or irradiation by introducing into a subject's tumor cells nucleic acid encoding a polypeptide having adenovirus E1A activity, expressing the E1A active polypeptide in the cells and finally, administering either a chemotherapeutic agent or irradiation. The invention also provides a method of treating cancer.Type: GrantFiled: May 9, 1997Date of Patent: August 8, 2000Assignee: La Jolla Cancer Research FoundationInventor: Steven M. Frisch
-
Patent number: 6069231Abstract: The present invention provides PR domain peptides, which are about 100 to about 120 amino acids in length and contain three highly conserved sequences of about 10 to about 12 amino acids, separated by less conserved sequences of about 20 to about 35 amino acids.Type: GrantFiled: August 18, 1995Date of Patent: May 30, 2000Assignee: La Jolla Cancer Research FoundationInventor: Shi Huang
-
Patent number: 6046162Abstract: A method of suppressing cell proliferation of a mammalian cell by contacting the cell with decorin.Type: GrantFiled: June 2, 1995Date of Patent: April 4, 2000Assignee: La Jolla Cancer Research FoundationInventors: Erkki I. Ruoslahti, Yu Yamaguchi
-
Patent number: 6020460Abstract: Novel synthetic Arg-Gly-Asp-containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occuring amino acid, or by other methods. In particular, there is provided a cyclic peptide having increased affinity and selectivity for the vitronectin receptor over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: December 14, 1994Date of Patent: February 1, 2000Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Patent number: 6017877Abstract: The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic amino acids adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic amino acid an adjacent positively charged amino acid. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.Type: GrantFiled: May 19, 1994Date of Patent: January 25, 2000Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig, Juerg F. Tschopp
-
Patent number: 6013625Abstract: The invention provides RGD containing peptides which are cyclized and contain hydrophobic moieties adjacent the carboxy terminus of the RGD sequence. Such peptides have an high affinity for the receptor IIb/IIIa and low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.Type: GrantFiled: October 12, 1994Date of Patent: January 11, 2000Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig
-
Patent number: 6004748Abstract: This invention provides a method of inhibiting the transcription of a gene, which is activated by AP-1 or an AP-1 component, comprising binding AP-1 or the component with a nuclear receptor so as to prevent the binding of AP-1 to the gene. The nuclear receptor can be the retinoic acid receptor, glucocorticoid receptor, vitamin D3 receptor, thyroid receptor, or estrogen receptor. Also provided is a composition of matter comprising AP-1 or an AP-1 component bound to a nuclear receptor. These methods and compositions can be used to treat arthritis and cancer.Type: GrantFiled: November 27, 1996Date of Patent: December 21, 1999Assignee: La Jolla Cancer Research FoundationInventors: Magnus Pfahl, Michael Karin
-
Patent number: 5994501Abstract: The peptide X-Arg-Gly-Asp-R-Y wherein X is H or at least one amino acid and Y is OH or at least one amino acid, and R is an amino acid selected from Thr or Cys, or other amino acid, having the same cell-attachment activity as fibronectin and the peptide X-Arg-Gly-Asp-Ser-Y, wherein X and Y, having said activity are disclosed.Type: GrantFiled: April 10, 1998Date of Patent: November 30, 1999Assignee: The La Jolla Cancer Research FoundationInventors: Erkki Ruoslahti, Michael Pierschbacher
-
Patent number: 5985827Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: June 2, 1995Date of Patent: November 16, 1999Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Patent number: 5981478Abstract: This invention is directed to novel integrin binding peptides. These peptides bind to .alpha..sub.v - of .alpha..sub.5 -containing integrins and can exhibit high binding affinity. They contain one of the following sequence motifs: RX.sub.1 ETX.sub.2 WX.sub.3 [SEQ ID NO: 1] (especially RRETAWA [SEQ ID NO: 8]); RGDGX [SEQ ID NO: 2], in which X is an amino acid with a hydrophobic, aromatic side chain; the double cyclic CX.sub.1 CRGDCX.sub.2 C [SEQ ID NO: 15]; and RLD. The peptides generally exhibit their highest binding affinity when they assume a conformationally stabilized configuration. This invention also provides methods of using these peptides.Type: GrantFiled: August 4, 1994Date of Patent: November 9, 1999Assignee: La Jolla Cancer Research FoundationInventors: Erkki Ruoslahti, Erkki Koivunen
-
Patent number: 5981468Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: June 2, 1995Date of Patent: November 9, 1999Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Patent number: 5955578Abstract: A conjugate of a synthetic polypeptide containing RGD or (dR) GD and a biodegradable polymer, such as hyaluronic acid or chondroitin sulfate is disclosed. Methods of making the conjugate and using it to aid wound healing by providing a temporary matrix are disclosed.Type: GrantFiled: June 5, 1995Date of Patent: September 21, 1999Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, James W. Polarek, Marianne P. Petrica, Erkki I. Ruoslahti
-
Patent number: 5955572Abstract: The present invention provides cyclic peptides that recognize the arginine-glycine-aspartic acid (RGD) motif characteristic of many integrin ligands. These cyclic RGD-binding peptides, which comprise the motif (W/P)DD(G/L)(W/L)(W/L/M), have a structure that functionally mimics the RGD-binding site on an integrin. The invention further provides an antibody selectively reactive with a cyclic RGD-binding peptide containing the sequence (W/P)DD(G/L)(W/L)(W/L/M). The invention also provides a method to reduce or inhibit cell attachment to an RGD-containing ligand using a cyclic RGD-binding peptide of the invention.Type: GrantFiled: May 14, 1998Date of Patent: September 21, 1999Assignee: La Jolla Cancer Research FoundationInventors: Erkki Ruoslahti, Renata Pasqualini
-
Patent number: 5916875Abstract: The peptide X-Arg-Gly-Asp-R-Y wherein X is H or at least one amino acid and Y is OH or at least one amino acid, and R is an amino acid selected from Thr or Cys, or other amino acid, having the same cell-attachment activity as fibronectin and the peptide X-Arg-Gly-Asp-Ser-Y, wherein X and Y, having said activity are disclosed.Type: GrantFiled: February 13, 1997Date of Patent: June 29, 1999Assignee: La Jolla Cancer Research FoundationInventors: Erkki Ruoslahti, Michael Pierschbacher
-
Patent number: 5912234Abstract: The present invention provides peptides having specificity for fibronectin-binding and vitronectin-binding integrins, and in particular for .alpha..sub.5 .beta..sub.1 integrin. These peptides are characterized by having the ability to interfere with extracellular matrix protein binding to integrins; to block attachment of cells expressing these integrins to extracellular matrix proteins; and to promote cell attachment when coated onto a surface.Type: GrantFiled: April 3, 1996Date of Patent: June 15, 1999Assignee: La Jolla Cancer Research FoundationInventors: Erkki Ruoslahti, Erkki Koivunen
-
Patent number: 5910451Abstract: The present invention provides substantially purified mammalian trophinin which can mediate cell adhesion. The invention also provides substantially purified trophinin-assisting proteins, which interact with trophinin to mediate cell adhesion. The invention further provides antibodies that are specifically reactive with trophinin or a trophinin-assisting protein. In addition, the invention provides active fragments of trophinin or trophinin-assisting proteins. The invention further provides a nucleic acid molecule encoding trophinin or a trophinin-assisting protein, vectors containing the nucleic acid molecules and host cells containing the vectors. The invention also provides a nucleotide sequence that can hybridize to a nucleic acid molecule encoding trophinin or a trophinin-assisting protein. The invention further provides methods to detect trophinin or a trophinin-assisting protein or a nucleic acid molecule encoding trophinin or a trophinin-assisting protein in a sample.Type: GrantFiled: October 10, 1996Date of Patent: June 8, 1999Assignee: La Jolla Cancer Research FoundationInventor: Michiko N. Fukuda
-
Patent number: 5906975Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: August 19, 1994Date of Patent: May 25, 1999Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Patent number: 5880092Abstract: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.Type: GrantFiled: June 2, 1995Date of Patent: March 9, 1999Assignee: La Jolla Cancer Research FoundationInventors: Michael D. Pierschbacher, Erkki I. Ruoslahti
-
Patent number: 5880267Abstract: The present invention provides substantially purified mammalian trophinin which can mediate cell adhesion. The invention also provides substantially purified trophinin-assisting proteins, which interact with trophinin to mediate cell adhesion. The invention further provides antibodies that are specifically reactive with trophinin or a trophinin-assisting protein. In addition, the invention provides active fragments of trophinin or trophinin-assisting proteins. The invention further provides a nucleic acid molecule encoding trophinin or a trophinin-assisting protein, vectors containing the nucleic acid molecules and host cells containing the vectors. The invention also provides a nucleotide sequence that can hybridize to a nucleic acid molecule encoding trophinin or a trophinin-assisting protein. The invention further provides methods to detect trophinin or a trophinin-assisting protein or a nucleic acid molecule encoding trophinin or a trophinin-assisting protein in a sample.Type: GrantFiled: October 24, 1996Date of Patent: March 9, 1999Assignee: La Jolla Cancer Research FoundationInventor: Michiko N. Fukuda